Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > iA Capital Markets: Buy rating and $1.70 target for MBX

<< Previous

Bullboard Posts

Next >>

Comment by rovanieon Dec 28, 2021 11:41am

122 Views

Post# 34265489

RE:RE:iA Capital Markets: Buy rating and $1.70 target for MBX

Nice to see the PO come in from Ontario. Not tying up all of MBXs production capabilities, so maybe another order from a significant customer would be nice. Kinlytic is still a long way off, and wouldn't count on it.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages